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Background: Major depressive disorders (MDD) are a debilitating and pervasive group of mental illnesses afflicting
many millions of people resulting in the loss of 110 million working days and more than 2,500 suicides per annum.
Adolescent MDD patients attending NHS clinics show high rates of recurrence into adult life. A meta-analysis of
recent research shows that psychological treatments are not as efficacious as previously thought. Modest treatment
outcomes of approximately 65% of cases responding suggest that aetiological and clinical heterogeneity may
hamper the better use of existing therapies and discovery of more effective treatments. Information with respect to
optimal treatment choice for individuals is lacking, with no validated biomarkers to aid therapeutic decision-making.
Methods/Design: Magnetic resonance-Improving Mood with Psychoanalytic and Cognitive Therapies, the
MR-IMPACT study, plans to identify brain regions implicated in the pathophysiology of depressions and
examine whether there are specific behavioural or neural markers predicting remission and/or subsequent
relapse in a subsample of depressed adolescents recruited to the IMPACT randomised controlled trial
(Registration # ISRCTN83033550).
Discussion: MR-IMPACT is an investigative biomarker component of the IMPACT pragmatic effectiveness trial.
The aim of this investigation is to identify neural markers and regional indicators of the pathophysiology of and
treatment response for MDD in adolescents. We anticipate that these data may enable more targeted treatment
delivery by identifying those patients who may be optimal candidates for therapeutic response.
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Major depressive disorders (MDD) are serious public
and individual mental health illnesses predicted to be
the leading health burden worldwide by 2030 [1]. First
episodes of MDD often occur during childhood or ado-
lescence, with additional episodes likely to recur in some
65% of cases [2,3]. Further to this, Harrington and Clark
[4] report that childhood or adolescence onsets of
affective disorder are evident in approximately 30% of
adult cases. Adolescence can therefore be considered a
critical period where the initial stages and trajectories of
depression emerge [5]. Prior history of depression is as-
sociated with an increased risk of recurrence of MDD ir-
respective of concomitant level of prior or subsequent
environmental adversity [6,7] indicating a key role for
the illness per se in influencing natural history within in-
dividuals and making the delivery of effective treatment
at the earliest stages of the illness highly important in re-
lapse prevention.
Tackling this debilitating illness most effectively at the
first emergence of an episode in adolescence could be
seen as a crucial prevention strategy that may reduce the
risk of recurrence of future episodes and prove integral
for the long-term improvement of individual health out-
comes. In this respect, structural and functional neuro-
imaging measures, either alone or in combination, have
been used to identify brain areas indicative of efficacious
treatment given in adulthood [8-10]; reviewed in [11,12].
Furthermore, structural and functional neuroimaging
measures could have important prognostic clinical po-
tential by identifying those individuals who are most
likely to benefit from one or more forms of treatment
[8,11].
Treatments for MDD in adolescence
The United Kingdom (UK) National Institute for Health
and Care Excellence (NICE) guidelines recommend a
stepped-care approach for patients with MDD, where
treatment options advance alongside escalating need for
care. Although not always successful in leading to remis-
sion, provision of treatment, either in the form of psy-
chotherapy, pharmacotherapy, or both, often is essential
in order to interrupt the cycle of episodic relapse and re-
currence in MDD. In adolescents with MDD, a form of
psychotherapy such as cognitive behavioral therapy
(CBT) is first provided which may or may not be accom-
panied by pharmacotherapy treatment with selective se-
rotonergic reuptake inhibitors (SSRIs) such as fluoxetine
(20 mg-60 mg).
A pragmatic randomised controlled superiority trial by
our group compared SSRI and specialist clinical care
(SCC) with a combined treatment regime of SCC + SSRI
+ CBT and showed that the addition of CBT was no
more effective than SCC + SSRI at effecting remission by28 weeks of treatment [13]. Although that study did not
have a CBT-only or non-treatment control group, March
and colleagues [14] noted that CBT alone was not super-
ior to placebo in effecting remission by 12 weeks and
both were less effective than fluoxetine alone or combi-
nation therapy.
Brain imaging studies of MDD in adults
The IMPACT and MR-IMPACT research programmes
aim to establish the extent to which psychotherapies
with or without fluoxetine diminish the risk for relapse
at 86 weeks after treatment and reveal neural regions or
patterns of activity associated with treatment remission,
recovery or relapse. A meta-analysis conducted by Fu
and colleagues [11] compared neuroimaging evidence
for volumetric and functional changes associated with
symptom improvement following treatment (pharmaco-
logical, psychological, and combined approaches) for
depression. Functional activity in bilateral regions of
pregenual anterior cingulate cortex (pgACC) and right
subgenual anterior cingulate cortex (sgACC)/medial
orbitofrontal cortex (OFC) positively correlated with treat-
ment response, with greater activity in those regions asso-
ciated with an increased likelihood of responding to
treatment for depression [11], mirroring findings from an
earlier study [8]. A negative correlation between activation
in right anterior insula and right putamen and treatment
response also was observed [11]. Notably, a recent report
by McGrath and colleagues [15] suggested that metabolic
activity in right anterior insula could differentiate pharma-
cological versus psychological treatment response in
patients with moderate to severe depression with the po-
tential to optimize initial treatment selection in MDD.
In terms of brain structural predictors of treatment re-
sponse, regional volume reductions in the right hippo-
campus, as determined through manual segmentation
techniques, were associated with poorer response to
treatment [11]. Although lacking sufficient power, re-
duced volume in bilateral dorsolateral prefrontal cortex
(dlPFC), a region involved in the cognitive regulation of
emotion, was associated with poorer response to treat-
ment for depression. It is noteworthy that a recent
meta-analysis of treatment effects in MDD observed
across fMRI studies also identified bilateral dlPFC as a
treatment-sensitive region [16]. Considered together,
treatment response in MDD appears to be predicted by
a number of key areas within the fronto-limbic network
[17-19] including pgACC, sgACC, hippocampus, and
prefrontal cortices. Increased activity in perigenual ACC
(pgACC and sgACC regions) has been linked to suc-
cessful treatment by pharmacological agents whereas
decreased activity in this region has been linked to
successful treatment by psychological therapy [8,9,20];
summarized in [12].
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limbic pathophysiology of MDD, disruption to other
neural and neuroendocrine circuits such as the hy-
pothalamic-pituitary-adrenal (HPA-axis), cortico-striato-
pallidal-thalamo-cortical (CSPTC) loop, default mode
network, and reward network (further discussed in
[12,16,21,22]) have been discussed in relation to MDD.
Following CBT treatment significant interaction effects
have been observed in the amygdala and dorsal ACC for
patients with MDD compared to healthy control par-
ticipants [20] with treatment normalizing the previously
elevated and reduced responding in these respective re-
gions. Interestingly, the meta-analysis by our group [16]
showed decreased functional activation in the amygdala
in adults with MDD relative to healthy controls, perhaps
indicating that the common notion of an over-active
limbic system in MDD is incorrect or that the treatment
strategies formerly undertaken by adults with MDD
elicit considerably sustained effects in the amygdala.
Dorsal ACC is not part of the fronto-limbic network
[19] but may modulate both reward and HPA axis net-
works [22,23], suggesting the interaction of multiple
neural systems in MDD [24]. In line with a multiple
systems approach, the amygdala is part of the fronto-
limbic circuit and CSPTC loop [16,19], and interacts
with the HPA-axis [21], thus disruption to this region
alone could lead to perturbations downstream affec-
ting many neural systems. Different subtypes of depres-
sion (some of which remain to be identified) could also be
associated with impairment to different neural systems, or
with disruption to multiple neural systems at varying
weights.
Brain imaging studies of MDD in adolescence
Given the aberrant patterns of brain structure and func-
tion observed in adults with MDD, we can ask whether
depression in adolescence is similar to depression in
adulthood and whether common neural mechanisms
underlie pharmacological and/or psychological effective-
ness in spite of developmental processes occurring in
the adolescent brain. Far fewer neuroimaging investiga-
tions of depression have been conducted in adolescents,
with no single meta-analysis performed to our know-
ledge. Recent studies, however, suggest similar pertur-
bations in brain structure and function in regions
including, but not limited to, dlPFC, OFC, sgACC, and
amygdala, irrespective of patient age [25-27]. Further-
more, fluoxetine may exert effects via common neural
mechanisms in both adolescents and adults with MDD
[26], and CBT treatment response was unaffected by age
in a small group of adolescents with MDD [28]. These
neuroimaging studies together suggest that MDD and
effective treatment thereof may be instantiated by com-
parable mechanisms in adolescents and adults.Limitations of neuroimaging studies of MDD
There are, however, several limitations of previous neu-
roimaging research studies of MDD. Often mixed are
cases that may represent distinct subtypes of MDD
hence limiting the generalizability of findings. Further-
more, many treatment investigations of MDD have not
examined treatment effects past 16 weeks, which is a
relatively short time window considering that recovery
may take up to 2 years in some cases [29], and that re-
mission rates are 50% in first episode cases of clinic
groups by 2 years [29]. Longitudinal investigations across
the entire period of recovery are needed to understand
why some individuals recover from MDD whereas
others do not. The sample sizes of many neuroimaging
studies are relatively small considering the substantial
clinical heterogeneity across MDD cases. A failure to
find statistically significant differences across the whole-
brain may have prompted some studies to investigate
case–control differences within hypothesis-driven re-
gions of interest (ROI), which apply more lenient criteria
for evaluating the statistical significance of results. When
coupled with a relatively underpowered sample, inad-
vertent consequences of adopting ROI approaches are
the potential to inflate Type I and Type II error rates
due to the possibility of scanning an unrepresentative
sample of MDD cases and a failure to include all regions
where significant differences may occur across groups or
conditions. Larger sample sizes permitting whole-brain
examinations of volumetric and functional activation dif-
ferences are therefore needed in order to better under-
stand the pathophysiology of depression in adolescence.
Aims
Neuroimaging examinations of adolescents with MDD
provide an opportunity to reveal and differentiate pa-
thophysiological and therapeutic neural structure and
function between first episode sporadic as well as at risk
recurrent forms of this disorder. Using a repeated-
measures design in selected cases that have completed
psychological treatment provides a longitudinal neuro-
imaging investigation of therapeutic effects that have
the added potential of revealing neural sites that con-
stitute state or trait markers of illness and treatment
insensitivity.
MR-IMPACT will therefore examine neural markers
of moderate to severe unipolar depression in adoles-
cence and neurobiological predictors of recovery from
depression. Specific objectives of MR-IMPACT are as
follows:
 To define the profile of brain structural and
functional differences in adolescent patients with
depression at baseline compared to a group of
healthy adolescent participants.
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functional activation and connectivity, focusing on
neural systems implicated in adult MDD (ACC and
other fronto-limbic components) as predictors of
symptomatic response to each of the three types of
psychological treatments in the short-to-medium
term (up to 86 weeks after the start of treatment).
 To measure changes in brain functional activation
and connectivity before and after a course of CBT
and development-related changes in brain function
measured in a comparison group of healthy
participants to permit identification of treatment-
related changes in brain function.
Methods/Design
Study overview
MR-IMPACT is a pragmatic effectiveness trial of de-
pression in adolescence. All adolescents enrolled in
MR-IMPACT are simultaneously taking part in the
Improving Mood with Psychoanalytic and Cognitive
Therapies (IMPACT) trial [30], and have been randomly
allocated to one of three forms of talking therapy (short-
term psychoanalytic psychotherapy [STPP], SCC, and
CBT; Figure 1). The IMPACT recruitment, baseline as-
sessment and randomization procedures can be found
together with the treatment protocol for each thera-
peutic arm in Goodyer et al. [30]. Another adjunct study
of IMPACT, IMPACT-genes and hormones, will collect
salivary cortisol pre- and post-therapy to assess HPA-
axis functioning [30]. In adherence to UK NICE guide-
lines, patients allocated to any treatment arm may also
be prescribed up to 50 mg of Fluoxetine for symptom
reduction in the presenting episode.
The study will be conducted in accordance with the
Declaration of Helsinki [31].
Study participants
The patient population will be recruited from a larger
cohort of young people with depression who have agreedFigure 1 The relation of the IMPACT trial to the MR-IMPACT study.to take part in the IMPACT trial. All eligible and inter-
ested patients residing in London or Cambridgeshire will
be invited to take part in MR-IMPACT, with enrolment
targeted to reach 120 adolescents (male and female)
aged 11 through 17 years who meet Diagnostic and Stat-
istical Manual of Mental Disorders (DSM-IV) criteria for
moderate to severe unipolar depression. Patients with
chronic or recurrent MDD are also included, as are
patients already taking antidepressant medication. A
detailed list of the study exclusion criteria is provided
below.
All patients will be provided an MR-IMPACT study
information leaflet and will provide verbal consent to
IMPACT research assistants to be contacted by tele-
phone by an MR-IMPACT researcher a minimum of
48 hours later for potential participation in the MR-
IMPACT study. Patients will be contacted to assess
interest in and eligibility for the magnetic resonance im-
aging (MRI) scan. Patients with MRI contraindication
will be ineligible and therefore excluded from the study
at this point. For eligible patients, if the patient so
chooses, one adult (typically a parent) may accompany
the adolescent patient into the scanner suite. For the pa-
tients requesting this option, the identified adult will be
screened over the telephone for MRI contraindications.
Eligible patients will be scheduled for an MRI appoint-
ment where they are remunerated £30 for their time and
inconvenience. Any fees incurred for travel to and from
the MRI appointment will be reimbursed to the adult ac-
companying the patient.
A group of healthy control young persons matched for
age, sex, intelligence quotient (IQ) and handedness will
be recruited into the study for comparison. A letter will
first be posted to all families with healthy adolescents
who had participated in a previous study (i.e. the
ROOTS study) [32]. The letter will describe the MR-
IMPACT study and the current recruitment of siblings
of ROOTS participants aged between 11 and 17 years,
and request that interested families contact a member of
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range a home visit. If needed, additional healthy control
adolescents will be recruited from local schools within
Cambridgeshire.
Prior to visiting the home, potential healthy control
families will be posted MR-IMPACT study information
sheets at least 48 hours in advance to allow ample time
to consider study participation. At the home visit the
study details will be reviewed prior to obtaining in-
formed assent and consent by potential participants and
their parent/caregiver, respectively. Screening for per-
sonal and family history of psychiatric illness and MRI
contraindication will then be conducted. In a private set-
ting, healthy adolescents will also be screened for history
of attempted suicide, suicidal thoughts or cutting beha-
viour. After the home visit eligible healthy adolescents
and their families will be contacted to arrange an MRI
appointment at their convenience where adolescents will
be given a stipend of £30 for their time and inconveni-
ence. Any expenses incurred for travel to and from the
MRI appointment will be reimbursed to the adult ac-
companying the healthy adolescent.
Screening and MRI assessment
At the MRI assessment adolescents and their parents
will be asked to review the study information sheet one
final time prior to signing the MR-IMPACT study assent
and consent forms. Adolescents will be re-screened for
presence of MRI contraindication, as will any adults re-
quested to accompany adolescents in the scanner suite.
Adolescents will then be asked to complete the Edinburgh
Handedness Inventory [33] and the Spielberger Trait
Anxiety Inventory [34]. In preparation for the tasks the
adolescent will be asked to complete in the MRI scanner,
three similar tasks brief in length will be practiced on a
computer in advance of the actual scan. The practice tasks
will be administered in the same order as the MRI tasks
are presented to minimise confusion. Patients will then be
asked to complete the Spielberger State Anxiety Inventory
[34] before attending the 1.5 hour MRI session. Upon
completion of the MRI session, patients will be asked to
complete the Bond-Lader Visual Analogue Scales [35] and
then the Mood and Feelings Questionnaire-Short ver-
sion [36]. Lastly, patients will be asked to complete
two computerised tasks in follow-up to one of the
completed fMRI tasks.
Eligibility criteria
All patient participants will be required to meet DSM-IV
criteria for moderate to severe MDD, as determined by
child and parent interviews using the Kiddie Schedule
for Affective Disorders and Schizophrenia-Present and
Lifetime version (K-SADS-PL) [37]. A second criterion
for inclusion within the IMPACT trial is a score of27 or more on the self-report Moods and Feelings
Questionnaire (MFQ).
Inclusion criteria
1. Aged 11 through 17 years.
2. Current DSM-IV unipolar MDD diagnoses with
moderate to severe impairment determined by child
and parent interviews using the K-SADS-PL.
3. Score of 27 or more on the MFQ.
Exclusion criteria
1. Alcohol dependence.
2. Drug dependence.
3. Pervasive developmental disorder or generalized
learning problem.
4. Pregnancy or breastfeeding.
5. Concurrent medication use that could adversely
interact with SSRIs.
6. MRI contraindication.
7. Brain abnormality.
8. Intolerance to the MRI environment.
In order to ensure that the patient sample remains
representative of the cases that undergo treatment
through National Health Service Child and Adoles-
cent Mental Health Services (NHS CAMHS), no fur-
ther exclusions are made.
Ethics
Ethical approval for the study was granted by
the Cambridgeshire 2 Research Ethics Committee,
Addenbrooke’s Hospital Cambridge, UK (REC reference:
09/H0308/168).
Assessments and outcome measures
Self-report battery
Edinburgh handedness inventory The Edinburgh Han-
dedness Inventory [33] assesses preferred hand use
across different tasks and generates a single score ran-
ging from −100 to +100 (i.e., the laterality quotient) indi-
cative of overall handedness laterality. Across a series of
tasks, participants are requested to indicate which hand
typically performs said task. In the event that neither
hand is the preferred hand, a score is evenly allocated to
both left and right hands. The measure is valid for use
across cultures and between sexes.
Spielberger state-trait anxiety inventory The
Spielberger State-Trait Anxiety Inventory (STAI) [34] is
comprised of two 20-item questionnaires that assess
both temporary fluctuations in, and long-standing ex-
perience of anxiety symptoms. When completing the
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whether each statement within a list of statements ap-
plies to them ‘not at all’, ‘somewhat so’, ‘moderately so’, or
‘very much so’ at that particular moment in time. Scores
indicative of a high internal consistency are more valid
than test-retest correlations when assessing the validity
of transitory measures such as the STAI-S. The median
alpha coefficient for the STAI-S was approximately 0.93,
while the median test-retest correlation was 0.330 [34].
When completing the STAI-Trait (STAI-T), participants
are asked to indicate how much each statement within a
list of statements applies to them in general (almost
never; sometimes; often; or almost always). The median
alpha coefficient was 0.90 for the STAI-T scale indicating
a high level of internal consistency, with test-retest cor-
relations observed to be reasonably high across high
school students, achieving a median-level of 0.695 [34].
The STAI-S anxiety questionnaire attempts to measure
current (i.e., temporary) feelings of tension, apprehen-
sion, worry and nervousness whereas the STAI-T anxiety
questionnaire attempts to measure long-standing indi-
vidual differences in anxiety susceptibility. State anxiety
scores can therefore be considered as reflecting the
intensity of anxious feelings and trait anxiety scores
can be considered as reflecting the frequency with
which feelings of anxiety are experienced. Scores ob-
tained from the STAI-S and STAI-T correlate positively
with each other, particularly in the case of sequential
administration.
Bond-lader visual analogue scales The Bond-Lader
Visual Analogue Scales (VAS) is a highly sensitive ques-
tionnaire comprised of several rating scales that can de-
tect subtle mood changes in a large sample of healthy
individuals aged 16–64 years [35]; c.f. [38]. The VAS
measures subjective feelings relative to 16 opposing
emotive word-pairs. Emotive word-pairs are presented
with one word appearing at each polar end of a single
line measuring 100 mm. Participants are asked to indi-
cate how they currently feel relative to the sixteen emo-
tive dimensions by drawing a perpendicular line on each
rating line. The length from the end of the line to the
participant’s mark is then measured to provide an overall
score for each of the 16 scales.
While items within the VAS were once thought to as-
sess mental alertness, physical alertness, calmness, and
other feelings [38], factor analysis of the measure in
healthy individuals has since revealed only three under-
lying scales: alertness; contentedness; and calmness [35].
Short mood and feelings questionnaire The Short
Mood and Feelings Questionnaire (SMFQ) [36] is a 13-
item self-report questionnaire that measures the pre-
sence and severity of depressive symptoms occurring inan individual over a two-week period. The scale derives
from the 33-item MFQ, with each item consisting of a
single statement (e.g., ‘I didn’t enjoy anything at all’)
rated by the respondent as ‘always true’, ‘mostly true’,
‘sometimes true’, or ‘never true’.
The SMFQ reviews the core set of depressive symp-
toms and has been shown to discriminate child psychi-
atric patients from pediatric controls, and depressed
from non-depressed participants in a general population
sample. The SMFQ correlates highly with more exten-
sive evaluations, like the Children’s Depression Inventory
(CDI) or the Diagnostic Interview Schedule for Children
(DISC), and has a robust single factor structure from
ages 6 to 16 years.
MRI assessment battery
Structural MRI datasets
A three-dimensional structural MRI (sMRI) will first be
obtained for all participants to exclude for brain ab-
normality. MR images will be acquired on a 3.0 Tesla
Magnetom Trio Tim scanner (Siemens, Surrey, England)
at the Wolfson Brain Imaging Centre, University of
Cambridge, UK. High-resolution dual echo sequences
will be acquired in the axial plane using proton den-
sity T2-weighted sequences (Axial PD-T2; 27 slices of
4.0 mm thickness, first echo time (TE) = 12.0 ms, second
TE = 104.0 ms, repetition time (TR) = 4.60s, flip angle =
150˚, field of view = 224 × 134 mm2, voxel size = 0.7 ×
0.7 × 4.0 mm3, series = interleaved). High-resolution T1-
weighted sequences will be acquired in the sagittal plane
using a three-dimensional magnetically prepared rapid
acquisition gradient echo sequence (3D-MPRAGE; 176
slices of 1.0 mm thickness, TE = 2.98 ms, TR = 2.30s, in-
version time = 900 ms, flip angle = 9˚, field of view =
240 × 256 mm2, voxel size = 1.0 × 1.0 × 1.0 mm3, series =
interleaved). All images will be examined and approved
for inclusion by a Consultant Radiologist specialising in
neuroanatomy. Grey and white matter maps will be ge-
nerated for each baseline scan.
Diffusion tensor imaging (DTI)
Whole brain data will be acquired and analysed for deri-
vation of fractional anisotropy measures of white matter
integrity and tractography of selected axonal tracts me-
diating connections between limbic and frontal regions
of interest. Thirteen diffusion-weighted directed volumes
and 5 volumes without diffusion-weighting (b = 0) will
be acquired (63 slices of 2.0 mm thickness, TE = 98 ms,
TR = 8.30s, field of view = 192 × 126 mm2, voxel size =
2.0 × 2.0 × 2.0 mm3, series = interleaved).
Functional MRI (fMRI) datasets
Echo-planar images (EPI) depicting blood oxygen level-
dependent (BOLD) contrast at a sampling time of
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three tasks and during rest. MR images will be acquired
on a 3.0 Tesla Magnetom Trio Tim scanner (Siemens,
Surrey, England) at the Wolfson Brain Imaging Centre,
University of Cambridge, UK. Radio frequency pulses
will be transmitted and received via a quadrature bird-
cage headcoil. To maximise magnetic field homogeneity,
an automatic shim will be applied prior to functional
data acquisition. MR data covering the whole brain will
be acquired using echo planar T2* weighted imaging.
For each functional task, 32 slices of data 3.0 mm in
thickness parallel to the anterior-posterior commissure
will comprise each volume of data collected (TE = 30 ms,
TR = 2 s, flip angle = 78˚, and interleaved series). The field
of view and voxel size will be 192 × 120 mm2 and 3.0 ×
3.0 × 3.0 mm3, respectively.
Implicit facial expression recognition task Facial ex-
pressions taken from the Facial Expressions of Emotion:
Stimuli and Tests (FEEST) [39] representing medium
and high intensity morphs of sadness and happiness are
presented together with neutral faces and crosshair fixa-
tions which will serve as a low-level baseline to control
for possible differences in activation of low-level visual
areas. Facial expressions from four male and four female
actors will be selected from the stimulus set based upon
similarities in Facial Action Coding System unit score
and high recognition ratings for happy, sad and neutral
expressions. A total of 96 trials will be presented (16
from each category) with all stimuli presented in random
order in an event-related design. A jittered stimulus
presentation will be used with a mean inter-trial interval
(ITI) of 3.0 seconds and a range of 1.0 to 6.0 seconds
following a Poisson distribution. Each stimulus will ap-
pear on the screen for 2 seconds and for each facial trial
adolescents will be asked to indicate the gender of the
face by depressing one of two keys on a button box. All
stimuli will be presented using Visual Basic software
(Microsoft), with the order of stimulus presentation
pseudo-randomized across participants to minimize ha-
bituation effects.
After each scan session participants will be asked to
use a 9-point Likert scale, with 1 and 9 representing low
and high intensities, respectively, to indicate how happy
and how sad each of the emotional faces appear.
fMRI data acquisition–implicit facial expression re-
cognition The scan length is approximately 8.5 minutes,
during which 249 volumes of fMRI data will be collected.
Emotional go/no-go task Happy, sad and neutral words
will be individually presented in a blocked paradigm de-
sign. The words presented are originally reported in
Murphy et al. [40], with no word overlapping with thewords used in the encoding and retrieval task described
below. Within each block of presented words partici-
pants will be instructed to respond by button-press to
words of a chosen target category (go), while withhol-
ding responses (no-go) to distracters selected from a dif-
ferent category. The task design will be similar to that
reported in Elliott et al. [41], with each word block last-
ing 24 seconds in length and consisting of 10 targets and
10 distractor words. A total of 21 word blocks will be
presented where six blocks of target sad words will be
presented in the context of happy (3 blocks) and neutral
(3 blocks) distractor words, six blocks of happy target
words will be presented in the context of sad (3 blocks)
and neutral (3 blocks) distractor words, and six blocks of
neutral target words will be presented in the context of
happy (3 blocks) and sad (3 blocks) distractor words.
Three baseline word blocks consisting of italicised words
(orthographic targets) presented in the context of plain
text distracter words will also be presented. A 12 second
rest block during which a crosshair fixation will appear for
the first 8 seconds and simple task instructions (e.g., “Press
for Sad words. Ignore Happy words.”) will appear for the
remaining 4 seconds prior to each word block. Within
every block, each word will be presented for 450 ms and
will be followed by a gray screen ITI of 750 ms.fMRI data acquisition–emotional go/no-go task The
scan length is approximately 13.5 minutes, during which
399 volumes of data will be collected.Encoding and retrieval task Anderson’s list of 555 per-
sonality trait words rated for likeableness [42] will be
used to construct a list of 90 unambiguously positive
and 90 unambiguously negative words. Participants will
first be asked to perform an explicit categorisation
(memory encoding) task and then an unanticipated inci-
dental memory (retrieval) task. During the encoding
task, 60 personality trait words, half of which are unam-
biguously positive, will be presented each for 500 ms
and participants will be requested to indicate whether
the word is likeable or dislikeable in the context of this
word being used to describe them. Each word will be
preceded by a black fixation cross centrally presented
against a solid gray background for 500 ms. Words will
be followed by a jittered ITI following a Poisson distri-
bution ranging from 1 to 6 seconds (mean of 3 seconds)
where a centrally-presented black fixation cross will ap-
pear against a solid gray background. For the memory re-
trieval task, 120 personality trait words will be presented,
of which half will be repeated from the categorisation task
and half will be new words (distractors) comprised of an
equal number of unambiguously positive and unambigu-
ously negative distractor words. Participants will be asked
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fore) or old (seen before).
fMRI data acquisition–encoding and retrieval task
The scan length is approximately 13 minutes, during
which 384 volumes of fMRI data will be collected.
Resting state Participants will be asked to lie at rest
with their eyes closed and try not to fall asleep during
continuous fMRI data acquisition.
fMRI data acquisition–resting state The scan length is
approximately 9 minutes, during which 265 volumes of
fMRI data will be collected. To measure the magnetic
field prior to and following resting state data acquisition
field maps with two echo times (TE1 = 5.19 ms, TE2 =
7.65 ms) will also be acquired with the positioning of the
participant kept consistent across the three scan se-
quences. Magnitude images for both echoes and esti-
mated field maps will be obtained.
Follow-up assessment
Patients who were randomized to the CBT arm of the
IMPACT clinical trial who have completed a minimum
of 6 out of a maximum of 20 offered CBT therapy
sessions will be invited back for a second MRI visit ap-
proximately 24 weeks following their first therapy ap-
pointment. All healthy comparison participants will be
invited back for a second MRI visit at least 24 weeks
from their first scan date to ensure a comparable length
of time has passed between scans across groups. Due to
financial constraints, no sMRI and DTI sequences will
be performed at the second MRI visit. All participants
will complete the same fMRI tasks collected during the
first MRI visit (e.g., implicit facial expression recogni-
tion, emotional go/no go, encoding and retrieval, and
resting state tasks). In line with procedures undertaken
at the first scan, STAI measures will be obtained prior to
scanning whereas SMFQ and Bond VAS measures will
be obtained after the scan.
Sample size and power calculations
To effectively test the presence of a relationship bet-
ween pre-treatment imaging markers and post-treatment
symptomatic response the study sample size will need to
be large enough to overcome the neuroimaging prob-
lem of multiple comparisons across the ~300,000 intra-
cerebral image voxels and also account for participant
attrition. The attrition rate observed during a similar
trial (i.e., Adolescent Depression Antidepressants and
Psychotherapy Trial [ADAPT]) with a 28-week follow-
up period was just 2% [43]. Allowing for an even greater
attrition rate of 20% on a pre-treatment sample size of
40 patients per treatment arm, it follows that 32 patientswill be available for post-treatment scans. Assuming an
effect size of the same size as that observed in a previous
study of adults with MDD (R ≥ 0.76 for grey matter vol-
ume [GMV] and symptom response in ACC) [8] and a
conservative two-tailed probability of p <0.001 to control
for multiple comparisons in a whole brain analysis of
imaging data, and at least 32 patients completing post-
treatment scans, the power to detect a true effect will be
at least 95%. Thus with pre-treatment imaging data from
40 patients per treatment arm, the study is strongly
powered to assess imaging predictors of recovery follo-
wing treatment for MDD.
To detect CBT-related changes in brain function, a pre-
vious fMRI study of adult MDD [9] and a pilot study
examining components of variance in a facial emotion
perception task [44] are used to inform calculations of
statistical power. Activation of the left amygdala by facial
emotion processing showed an effect of antidepressant
treatment of d = 1.02 [9]. A similar effect size of CBT will
be assumed for the current study, with empirical estimates
of between-subject and between-session variance in amyg-
dala response [44] suggesting that a minimum power of
80% will be needed for detection of a true treatment effect.
Considered together with a false positive rate of 5%, a
minimum of 30 participants will be needed for the detec-
tion of CBT-related changes in brain function. The effects
obtained in 40 patients in the CBT arm, compared to 40
healthy adolescents, should therefore be sufficiently po-
werful in size to detect therapeutic changes in amygdala
activation equivalent to that observed from antidepressant
medication treatment studies of adult patients with MDD.
sMRI data analysis plan
Whole brain, multi-channel segmentation [45] and voxel-
based morphometry [46] will be used to generate GMV
maps from each baseline scan for co-registration into
Montreal Neurological Institute (MNI) standard space
[47]. Whole brain voxel-based morphometry will first be
used to assess the presence of pre-treatment anatomical
differences between patients and controls and to explore
regions where variation in grey or white matter signifi-
cantly predict treatment-specific or treatment-general re-
sponses [8]. The multivariate technique of partial least
squares [48] will also be used to identify patterns of grey
matter variation that optimally correlate with treatment
response. In an effort to test our hypotheses comprehen-
sively, we will also use the MNI template [49] to anatom-
ically parcellate a priori regions of interest including, but
not limited to, subgenual, pregenual and dorsal ACC,
amygdala, hippocampus, and prefrontal cortex, where the
presence of both group differences in GMV and associa-
tions with treatment-specific symptom reductions will be
assessed. Non-parametric statistical methods with correc-
tion for multiple comparisons [50-52] will be used.
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and mean diffusivity maps will be created using the
Functional Magnetic Resonance Imaging of the Brain
(FMRIB) diffusion toolbox in FMRIB Software Library
(FSL) [53] by estimating diffusion tensors at each intrace-
rebral voxel prior to using a b = 0 image for mapping into
MNI standard space. As with the sMRI data, between-
group differences and predictors of treatment response in
fractional anisotropy and diffusivity measures will be iden-
tified across the whole brain and in a priori regions of
interest. For further exploration of group differences and
associations with treatment outcome, anatomical connec-
tions between frontal and limbic cortex will be measured
using probabilistic tractography [54-56].
fMRI data analysis plan
Standard preprocessing methods for all datasets will
include correction for head movement [52] and ap-
propriate control for potential confounds to BOLD sig-
nal dynamics such as fluctuation in cardiorespiratory
rhythms [57]. A general linear model will be used to
convolve the hemodynamic response function with
fMRI-related contrasts of interest to provide estimates of
BOLD signal on a voxel-by-voxel basis in MNI standard
space. Hypotheses will be tested using the same ap-
proach as that undertaken in the sMRI data analyses,
where between-group differences and predictors of treat-
ment response in pretreatment BOLD signal will be
identified across the whole brain and in a priori regions
of interest. CBT-related changes in functional activa-
tion will also be examined. Univariate analyses will be
followed-up by the multivariate approach of partial
least squares to identify task-related patterns of func-
tional activation relating to therapeutic outcome.
Resting state fMRI data will be analysed in a similar
fashion to the functional task data. The Hurst exponent
will first be estimated at each voxel in the resting state
data. The Hurst exponent measures the randomness of a
data set and as such, has been shown to be sensitive
to the effects of disease and drug treatment [58,59].
Between-group differences and predictors of treatment
response in pretreatment BOLD signal will first be
identified across the whole brain and then in a priori
regions of interest. CBT-related changes in the Hurst
exponent will also be examined.
We will also measure functional connectivity between
regions within the fronto-limbic system and construct
graphical models that summarise the topological proper-
ties of fronto-limbic and whole brain networks [60,61] in
the resting state data. Similar network analysis methods
may then be applied to the DTI data set, thereby per-
mitting an integrated functional and structural analysis
of network abnormalities in depression. Nonparametric
statistical methods of inference will again be appliedto statistically evaluate fractal and network parameters
[50-52,62].
Longitudinal data analysis plan
For the fMRI datasets collected at baseline and 24 weeks,
we will fit a balanced, mixed effects 2 × 2 (group × time)
analysis of variance (ANOVA) model to the brain acti-
vation data acquired on patients treated with CBT and
healthy adolescents. A significant group × time inter-
action will identify the effect of CBT, for which appro-
priate post-hoc tests will be performed. Nonparametric
statistical methods of inference correcting for multiple
comparisons will be applied to statistically evaluate the
main effects of group and time point, and any group ×
time interaction [50-52].
Discussion
An important challenge to adolescent mental health ser-
vices is the provision of appropriate and effective treat-
ment to adolescents in need at the earliest possible point
in time. To overcome this challenge, accuracy in both
diagnostic assessment and prognostic evaluation of pa-
tients are critical, but as yet clinicians possess no ob-
jective tools for either. Diagnostic assessments rely on
subjective retrospective information transmission from
patient and/or parent to clinician whereas potential prog-
nostic indicators of treatment outcome, such as depressive
symptom severity or suicidal tendencies, are poor [43].
Therefore the overall aim of MR-IMPACT is to identify
and evaluate objective neurobiological markers of depres-
sive illness in adolescence and prognostic indicators of
recovery following psychological treatment for depression.
Neural markers of depression in adolescence will be
characterized by comparing structural and functional dif-
ferences in patients with MDD prior to treatment against
a group of healthy adolescent participants matched for
demographic characteristics such as age, sex and IQ.
Treatment-related changes will be identified by measuring
changes in brain functional activation and connectivity
prior to treatment and following at least six attended ses-
sions of CBT. A placebo-controlled trial would have been
an optimal method for assessing treatment-related chan-
ges, but impossible due to ethical constraints. Therefore,
changes in brain function in healthy adolescents will also
be measured at a second time point matched in length to
that of the depressed group to ensure that functional
changes indicative of adolescent development are not mis-
identified as changes related to CBT treatment.
Short, medium, and long-term predictors of response
to treatment by CBT, STPP, and SCC will be identified
by relating the extent and rate of improvement in
depressive symptoms with pre-treatment measures of
brain structure, functional activity and connectivity. To
comprehensively test the relationship between structural
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of the depressions we will also perform multivariate ana-
lyses focusing on neural systems implicated in adult MDD
and on the fronto-limbic system in particular. The longer-
term aim of MR-IMPACT, IMPACT, and other adjunct
IMPACT studies includes whether relapse and recurrence
of depression can be successfully predicted using neurobio-
logical, behavioural, environmental, and genetic indices.
Despite the aim of differentiating state from trait markers
of depressive illnesses in adolescence and predictors treat-
ment response, our study is not without limitations. One
limitation, common to all longitudinal treatment studies,
includes an inability to disaggregate neural markers of
illness and neural indicators of treatment-general non-
response (i.e., refractory depression). While the simple
comparison of treatment responders with treatment non-
responders would indicate regions involved in treatment-
specific response, the possibility remains that patients
would have responded to alternative treatment strategies
had they been provided. One way we could have examined
neural markers of illness would have been to include
within the longitudinal design a group of currently healthy
adolescents with a predisposition for developing MDD.
However, in order to achieve sufficient statistical power to
ensure reliable and reproducible effects, this would have
necessitated the initial recruitment of a much larger sam-
ple of adolescents than was realistically feasible and so we
opted for the current design. Bearing this limitation in
mind, we hope the study results will assist in the provision
of more targeted treatment strategies to adolescent pa-
tients with MDD.
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